ECDC Director Marc Sprenger at the European Parliament Committee on the Environment, Public Health and Food Safety (ENVI) stressed the importance of the EU’s continuous commitment in the fight against hepatitis B and hepatitis C.
In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
The authors retrospectively analyzed hepatitis A virus (HAV) seroprevalence in travellers who had been born and lived at least 1 year in a developing country, wanted to travel to a hepatitis A endemic area, and consulted at the vaccination centre of the Institut Pasteur of Paris between September 1, 2008 and February 28, 2010. HAV seroprevalence was 82.4 % for a population of 646 immigrants for whom data were available
A four-fold increased incidence of narcolepsy in vaccinated children/adolescents compared to unvaccinated children was observed in this register-based cohort study.
The overall objective is to improve early detection and response to outbreak of zoonotic diseases at the EU level through strengthened collaboration with the animal health sector and other agencies and organizations working at the animal-human interface.
The first annual meeting of the European hepatitis B and C surveillance network takes place on 23-24 March 2011. Since 2009, ECDC has worked on preparing the enhanced surveillance of hepatitis B and C at EU/EEA level by establishing a network for hepatitis B and C surveillance and by carrying out a survey on prevention and surveillance activities in the Member States.
ECDC and EFSA have just launched the annual report on zoonoses and food-borne outbreaks in the European Union for 2009. The report shows that Salmonella cases in humans fell by 17% in 2009, marking a decrease for the fifth consecutive year
First annual meeting of the network since it was transferred to ECDC in March 2010. Among the objectives of the meeting is to to present the epidemiological situation of diphtheria in Europe for 2009.
Each year in February WHO convenes a meeting with advisers from the WHO Influenza Collaborating Centres and Essential Reference laboratories in order to achieve consensus and advise WHO on the optimal formulation of seasonal influenza vaccines for the next influenza season.